ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER

被引:91
|
作者
HUNG, MC [1 ]
ZHANG, X [1 ]
YAN, DH [1 ]
ZHANG, HZ [1 ]
HE, GP [1 ]
ZHANG, TQ [1 ]
SHI, DR [1 ]
机构
[1] SHANGHAI MED UNIV, HOSP CANC, INST CANC, DEPT PATHOL, SHANGHAI 20032, PEOPLES R CHINA
关键词
HER-2; C-ERB-2/NEU; ONCOGENE; OVARIAN CANCER;
D O I
10.1016/0304-3835(92)90166-S
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the c-erbB-2/neu protooncogene has recently been shown in ovarian tumors collected from the United States. It is known that environmental and cultural factors may contribute to certain types of cancer, therefore, we examined expression of c-erbB-2/neu in ovarian tumors collected from China by immunohistochemical staining. Out of 81 tumor specimens, 57 (70.4%) were found to be immunopositive, whereas only one out of 17 (5.9%) normal ovarian tissue samples was slightly positive. Our results indicate that overexpression of c-erbB-2/neu is a general phenomenon for ovarian cancer regardless of different population. To search for a c-erbB/neu overexpressing cell line for future study on molecular mechanism, we also analyzed 13 cancer cell lines from the female genital tract for expression of c-erbB-2/neu. The c-erbB-2/neu RNA was found to be overexpressed at least 100-fold in one of the four ovarian cancer cell lines examined. An aberrant c-erbB-2/neu RNA was also found to be overexpressed in this cell line. Southern blot analysis indicated that the c-erbB-2/neu was amplified 2 - 4-fold in this line, and some of these alleles have structural alteration which may account for expression of the aberrant c-erbB-2/neu RNA. Since the 2 - 4-fold gene amplification is not proportional to the > 100-fold overexpression in RNA, other mechanisms such as transcriptional or post-transcriptional control must be involved in overexpression of this gene in ovarian cancer.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 50 条
  • [41] Determination of c-erbB-2 or HER-2/neu as indicator of prognosis in breast cancer
    Müller, L
    Illiger, HJ
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (01) : 44 - 46
  • [42] Prognostic significance of p105 (c-erbB-2, HER2/neu) serum levels in patients with ovarian cancer
    Meden, H
    Marx, D
    Schauer, A
    Wuttke, W
    Kuhn, W
    ANTICANCER RESEARCH, 1997, 17 (1B) : 757 - 760
  • [43] GENE AMPLIFICATION AND EXPRESSION OF THE NEU (C-ERBB-2) SEQUENCE IN HUMAN MAMMARY-CARCINOMA
    FONTAINE, J
    TESSERAUX, M
    KLEIN, V
    BASTERT, G
    BLIN, N
    ONCOLOGY, 1988, 45 (05) : 360 - 363
  • [44] EXPRESSION OF THE C-ERBB-2 (NEU) GENE IN NORMAL AND BENIGN PROLIFERATIVE BREAST-TISSUE
    YEH, I
    KEYKAH, S
    WILLIAMS, T
    LABORATORY INVESTIGATION, 1991, 64 (01) : A16 - A16
  • [45] C-ERBB-2 AND HUMAN CANCER
    PASTAN, I
    JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (12): : 1336 - 1337
  • [46] EXPRESSION OF THE C-ERBB-2 (HER-2/NEU) ONCOPROTEIN IN HUMAN PROSTATIC-CARCINOMA
    KUHN, EJ
    KURNOT, RA
    SESTERHENN, IA
    CHANG, EH
    MOUL, JW
    JOURNAL OF UROLOGY, 1993, 150 (05): : 1427 - 1433
  • [47] Characterization of a c-erbB-2 ribozyme in ovarian cancer cells using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein
    Wiechen, K
    Zimmer, C
    Anderer, U
    Turzynski, A
    Dietel, M
    CANCER GENE THERAPY, 1997, 4 (05) : 301 - 301
  • [48] EVIDENCE BY INSITU HYBRIDIZATION THAT C-ERBB-2 PROTOONCOGENE EXPRESSION IS A MARKER OF MALIGNANCY AND IS EXPRESSED IN LUNG ADENOCARCINOMAS
    PAAKKO, P
    NUORVA, K
    KAMEL, D
    SOINI, Y
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1992, 7 (03) : 325 - 334
  • [49] RARE OCCURRENCE OF AMPLIFICATION OF HER-2 (ERBB-2/NEU) ONCOGENE IN OVARIAN-CANCER PATIENTS
    IMYANITOV, EN
    CHERNITSA, OI
    SEROVA, OM
    KNYAZEV, PG
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) : 1300 - 1300
  • [50] DISTRIBUTION OF NEU (C-ERBB-2) PROTEIN IN HUMAN-SKIN
    MAGUIRE, HC
    JAWORSKY, C
    COHEN, JA
    HELLMAN, M
    WEINER, DB
    GREENE, MI
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 92 (06) : 786 - 790